Premium
Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation
Author(s) -
Chien MingNan,
Yang PoSheng,
Hsu YiChiung,
Liu TsangPai,
Lee JieJen,
Cheng ShihPing
Publication year - 2018
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.25385
Subject(s) - telomerase reverse transcriptase , biology , telomerase , gene , promoter , cancer research , papillary thyroid cancer , thyroid cancer , transcriptome , mutant , telomere , reverse transcriptase , thyroid carcinoma , mutation , cancer , microbiology and biotechnology , gene expression , thyroid , genetics , rna
Background Telomerase reverse transcriptase (TERT) promoter mutations have recently been identified as an important prognostic factor in thyroid cancer. Studies suggest that TERT may have noncanonical functions beyond telomere maintenance. Methods Clinicopathological information and transcriptome data for papillary thyroid carcinoma (PTC) samples were obtained from The Cancer Genome Atlas (TCGA). Propensity score matching was performed to adjust for potential confounding variables between the TERT promoter wild‐type group and the mutant group. Gene expression data of 36 patients in the mutant group were systemically compared to those of 72 patients in the wild‐type group. Results Tumors with TERT promoter mutations had a higher TERT expression. Pathways central to DNA damage responses and cell cycle regulation were significantly enriched among 888 upregulated genes. Transporter and metabolic activities were overrepresented among 799 downregulated genes. There was no difference in the expression of most of the thyroid differentiation genes. Conclusion The TERT promoter mutations were associated with proliferative and metabolic alterations in PTC.